Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Prasinezumab (PRX002/RG7935) is an investigational monoclonal antibody that targets alpha-synuclein, a protein that is believed to misfold and aggregate to form the protein structures that are highly implicated in Parkinson's disease pathology. Prasinezumab targets alpha-synuclein and is being developed through a worldwide collaboration with Roche as a potentially disease modifying therapy that is designed to slow or reduce the neurodegeneration associated with alpha-synuclein misfolding and/or its transmission.
仅用于科研。不用于诊断过程。未经明确授权不得转售。